Experimental Therapeutic Solutions for Behcet’s Disease

References

• Alpsoy E. Behçet’s disease: A comprehensive review with a focus on epidemiology, etiology and clinical features, and management of mucocutaneous lesions. J Dermatol. 2016;43(6):620–632. doi:10.1111/1346-8138.13381
   PubMed Web of Science ®Google Scholar
• Azizlerli G, Kose AA, Sarica R, et al. Prevalence of Behcet’s disease in Istanbul, Turkey. Int J Dermatol. 2003;42:803–806.
   PubMed Web of Science ®Google Scholar
• Alpsoy E, Zouboulis CC, Ehrlich CE. Mucocutaneous lesions of Behcet’s disease. Yonsei Med J. 2007;48:573–585.
   PubMed Web of Science ®Google Scholar
• Alpsoy E, Donmez L, Onder M, et al. Clinical features and natural course of Behcet’s disease in 661 cases: a multicentre study. Br J Dermatol. 2007;157:901–906.
   PubMed Web of Science ®Google Scholar
• Kural-Seyahi E, Fresko I, Seyahi N, et al. The long-term mortality and morbidity of Behcet syndrome: a 2-decade outcome survey of 387 patients followed at a dedicated center. Medicine. 2003;82:60–76.
   PubMed Web of Science ®Google Scholar
• Mumcu G, Yay M, Aksoy A, et al. Predictive factors for work-day loss in Behçet’s syndrome: A multi-center study. Int J Rheum Dis. 2020;23:240–246.
   Web of Science ®Google Scholar
• Yazici H, Esen F. Mortality in Behçets syndrome. Clin Exp Rheumatol. 2008;26(5 Suppl 51):S138.
   Google Scholar
• Ugurlu N, Bozkurt S, Bacanli A, Akman Karakas A, Uzun S, Alpsoy E. The natural course and factors affecting severity of Behçet’s disease: a single-center cohort of 368 patients. Rheumatol Int. 2015;35:2103–2107.
   PubMed Web of Science ®Google Scholar
• International Study Group for Behcet’s Disease. Criteria for diagnosis of Behçet’s disease. Lancet. 1990;335:1078–1080.
   PubMed Web of Science ®Google Scholar
• Sallakci N, Bacanli A, Coskun M, Yavuzer U, Alpsoy E, Yegin O. CTLA-4 gene 49A/G polymorphism in Turkish patients with Behcet’s disease. Clin Exp Dermatol. 2005;30(5):546–550. doi:10.1111/j.1365-2230.2005.01846.x
   Web of Science ®Google Scholar
• Behçet H. Uber rezidivierende aphthose, durch ein Virus verursachte Geschwure, am Mund, am Auge, und an den Genitalien. Dermatol Wochenschr. 1937;105:1152–1157.
   Google Scholar
• Lehner T. The role of heat shock protein, microbial and autoimmune agents in the aetiology of Behget’s disease. Int Rev Immunol. 1997;14(1):21–32. doi:10.3109/08830189709116842
   PubMedGoogle Scholar
• Studd M, McCance DJ, Lehner T. Detection of HSV-1 DNA in patients with Behcet’s syndrome and in patients with recurrent oral ulcers by the polymerase chain reaction. J Med Microbiol. 1991;34(1):39–43. doi:10.1099/00222615-34-1-39
   Web of Science ®Google Scholar
• Mumcu G, et al. Oral health is impaired in Behcet’s disease and is associated with disease severity. Rheumatology. 2004;43(8):1028–1033. doi:10.1093/rheumatology/keh236
   Web of Science ®Google Scholar
• Kaneko F, Oyama N, Nishibu A. Streptococcal infection in the pathogenesis of BehÇet’s disease and clinical effects of minocycline on the disease symptoms. Yonsei Med J. 1997;38(6):444–454. doi:10.3349/ymj.1997.38.6.444
   Google Scholar
• Mizushima Y, Matsuda T, Hoshi K, Ohno S. Induction of Behçet’s disease symptoms after dental treatment and streptococcal antigen skin test.. J Rheumatol. 1988;15(6):1029–1030.
   Web of Science ®Google Scholar
• Alpsoy E. Behçet’s disease: treatment of mucocutaneous lesions.. Clin Exp Rheumatol. 2005;23(4):532–539.
   Web of Science ®Google Scholar
• Akman A, Kacaroglu H, Donmez L, Bacanli A, Alpsoy E. Relationship between periodontal findings and Behçet’s disease: a controlled study. J Clin Periodontol. 2007;34:485–491.
   PubMed Web of Science ®Google Scholar
• Celenligil-Nazliel H, Kansu E, Ebersole J. Periodontal findings and systemic antibody responses to oral microorganisms in Behçet’s disease. J Periodontol. 1999;70:1449–1456.
   PubMed Web of Science ®Google Scholar
• Coit P, Mumcu G, Ture-Ozdemir F, et al. Sequencing of 16S rRNA reveals a distinct salivary microbiome signature in Behcet’s disease. Clin Immunol. 2016;169:28–35.
   PubMed Web of Science ®Google Scholar
• Consolandi C, Turroni S, Emmi G, et al. Behcet’s syndrome patients exhibit specific microbiome signature. Autoimmun Rev. 2015;14:269–276.
   PubMed Web of Science ®Google Scholar
• Oezguen N, Yalcinkaya N, Kücükali CI, et al. Microbiota stratification identifies disease-specific alterations in neuro-Behçet’s disease and multiple sclerosis. Clin Exp Rheumatol. 2019;37 Suppl 121(6):58–66.
   PubMed Web of Science ®Google Scholar
• Shimizu J, Kubota T, Takada E, et al. Bifidobacteria abundance-featured gut microbiota compositional change in patients with Behcet’s disease. PLoS One. 2016;11:e0153746.
   Web of Science ®Google Scholar
• Shimizu J, Kubota T, Takada E, et al. Relative abundance of Megamonas hypermegale and Butyrivibrio species decreased in the intestine and its possible association with the T cell aberration by metabolite alteration in patients with Behcet’s disease. Clin Rheumatol. 2019;38:1437–1445.
   Web of Science ®Google Scholar
• Leccese P, Alpsoy E. Behçet’s Disease: an Overview of Etiopathogenesis. Front Immunol. 2019;10(10):1067. doi:10.3389/fimmu.2019.01067
   Web of Science ®Google Scholar
• de Menthon M, Lavalley MP, Maldini C, Guillevin L. Mahr A. HLA-B51/B5 and the risk of Behçet’s disease: a systematic review and meta-analysis of case-control genetic association studies. Arthritis Rheum. 2009;61:1287–1296.
   PubMed Web of Science ®Google Scholar
• Gul A. Genetics of Behçet’s disease: lessons learned from genomewide association studies. Curr Opin Rheumatol. 2014;26:56–63.
   PubMed Web of Science ®Google Scholar
• Hughes T, Coit P, Adler A, et al. Identification of multiple independent susceptibility loci in the HLA region in Behcet’s disease. Nat Genet. 2013;45:319–324.
   PubMed Web of Science ®Google Scholar
• Takeuchi M, Mizuki N, Meguro A, et al. Dense genotyping of immune-related loci implicates host responses to microbial exposure in Behçet’s disease susceptibility. Nat Genet. 2017;49:438–443.
   PubMed Web of Science ®Google Scholar
• Hou S, Yang Z, Du L, et al. Identification of a susceptibility locus in STAT4 for Behçet‘s disease in Han Chinese in a genome-wide association study. Arthritis Rheum. 2012;64:4104–4113.
   PubMed Web of Science ®Google Scholar
• Mizuki N, Meguro A, Ota M, et al. Genome-wide association studies identify IL23R-IL12RB2 and IL10 as Behçet’s disease susceptibility loci. Nat Genet. 2010;42:703–706.
   PubMed Web of Science ®Google Scholar
• Salmaninejad A, Gowhari A, Hosseini S, et al. Genetics and immunodysfunction underlying Behçet’s disease and immunomodulant treatment approaches. J Immunotoxicol. 2017;14:137–151.
   PubMed Web of Science ®Google Scholar
• McGonagle D, Aydin SZ, Gül A, Mahr A, Direskeneli H. ‘MHC-I-opathy’ — unified concept for spondyloarthritis and Behçet disease. Nat Rev Rheumatol. 2015;11:731–740.
   PubMed Web of Science ®Google Scholar
• Remmers EF, Cosan F, Kirino Y, et al. Genome-wide association study identifies variants in the MHC class I, IL10, and IL23R-IL12RB2 regions associated with Behçet’s disease. Nat Genet. 2010;42:698–702.
   PubMed Web of Science ®Google Scholar
• Kirino Y, Bertsias G, Ishigatsubo Y, et al. Genome-wide association analysis identifies new susceptibility loci for Behçet’s disease and epistasis between HLA-B-51 and ERAP1. Nat Genet. 2013;45:202–207.
   PubMed Web of Science ®Google Scholar
• Ombrello MJ, Kirino Y, de Bakker PI, Gül A, Kastner DL, Remmers EF. Behcet disease-associated MHC class I residues implicate antigen binding and regulation of cell-mediated cytotoxicity. Proc Natl Acad Sci. 2014;111:8867–8872.
   PubMed Web of Science ®Google Scholar
• Guasp P, Alvarez-Navarro C, Gomez-Molina P, et al. The Peptidome of Behçet’s Disease-Associated HLA-B*51:01 Includes Two Subpeptidomes Differentially Shaped by Endoplasmic Reticulum Aminopeptidase 1. Arthritis Rheumatol. 2016;68:505–515.
   PubMed Web of Science ®Google Scholar
• Padula MC, Leccese P, Pellizzieri E, et al. Distribution of rs17482078 and rs27044 ERAP1 polymorphisms in a group of Italian Behçet’s syndrome patients: a preliminary case-control study. Intern Emerg Med. 2019;14:713–718.
   PubMed Web of Science ®Google Scholar
• Giza M, Koftori D, Chen L, Bowness P. Is Behçet’s disease a ‘class 1-opathy’? The role of HLA-B*51 in the pathogenesis of Behçet’s disease. Clin Exp Immunol. 2018;191:11–18.
   Web of Science ®Google Scholar
• Deniz R, Tulunay-Virlan A, Ture Ozdemir F, et al. Th17-Inducing Conditions Lead to in vitro Activation of Both Th17 and Th1 Responses in Behcet’s Disease. Immunol Invest. 2017;46:518–525.
   PubMed Web of Science ®Google Scholar
• Alpsoy E, Kodelja V, Goerdt S, Orfanos CE, Zouboulis CC. Serum of patients with Behçet’s disease induces classical (pro-inflammatory) activation of human macrophages in vitro. Dermatology. 2003;206(3):225–232.
   Web of Science ®Google Scholar
• Greco A, De Virgilio A, Ralli M, et al. Behçet’s disease: new insights into pathophysiology, clinical features and treatment options. Autoimmun Rev. 2018;17:567–575.
   PubMed Web of Science ®Google Scholar
• Eksioglu-Demiralp E, Direskeneli H, Kibaroglu A, Yavuz S, Ergun T, Akoglu T. Neutrophil activation in Behçet’s disease. Clin Exp Rheumatol. 2001;19(5Suppl. 24):S19–S24.
   Google Scholar
• Becatti M, Emmi G, Silvestri E, et al. Neutrophil activation promotes fibrinogen oxidation and thrombus formation in Behçet disease. Circulation. 2016;33:302–311.
   Web of Science ®Google Scholar
• Yavuz S, Akdeniz T, Hancer V, Bicakcigil M, Can M, Yanikkaya-Demirel G. Dual effects of testosterone in Behçet’s disease: implications for a role in disease pathogenesis. Genes Immun. 2016;17:335–341.
   PubMed Web of Science ®Google Scholar
• Hasan MS, Ryan PL, Bergmeier LA, Circulating FF. NK cells and their subsets in Behçet’s disease. Clin Exp Immunol. 2017;188:311–322.
   Web of Science ®Google Scholar
• Yamaguchi Y, Takahashi H, Satoh T, et al. Natural killer cells control a T-helper 1 response in patients with Behçet’s disease. Arthritis Res Ther. 2010;12:R80.
   PubMed Web of Science ®Google Scholar
• Shimizu J, Takai K, Fujiwara N, et al. Excessive CD4+ T cells co-expressing interleukin-17 and interferon-γ in patients with Behçet’s disease. Clin Exp Immunol. 2012;168:68–74.
   PubMed Web of Science ®Google Scholar
• Chi W, Zhu X, Yang P, et al. Upregulated IL-23 and IL-17 in Behçet patients with active uveitis. Invest Ophthalmol Vis Sci. 2008;49:3058–3064.
   PubMed Web of Science ®Google Scholar
• Ekinci NS, Alpsoy E, Karakas AA, Yilmaz SB, Yegin O. IL-17A has an important role in the acute attacks of Behçet’s disease. J Invest Dermatol. 2010;130:2136–2138.
   PubMed Web of Science ®Google Scholar
• Touzot M, Cacoub P, Bodaghi B, Soumelis V, Saadoun D. IFNa induces IL-10 production and tilt the balance between Th1 and Th17 in Behçet disease. Autoimmun Rev. 2015;14:370–375.
   PubMed Web of Science ®Google Scholar
• Lee YJ, Horie Y, Wallace GR, et al. Genome-wide association study identifies GIMAP as a novel susceptibility locus for Behçet’s disease. Ann Rheum Dis. 2013;72:1510–1516.
   PubMed Web of Science ®Google Scholar
• Tong B, Liu X, Xiao J, Su G. Immunopathogenesis of Behcet’s Disease. Front Immunol. 2019;29(10):665.
   Web of Science ®Google Scholar
• Alpsoy E, Akman A. Behçet’s disease: an algorithmic approach to its treatment. Arch Dermatol Res. 2009;301:693–702.
   PubMed Web of Science ®Google Scholar
• Oh SH, Han EC, Lee JH. Comparison of the clinical features of recurrent aphthous stomatitis and behcet’s disease. clin exp dermatol. 2009; 34: 208-12.nakamura k, iwata y, asai j, kawakami t, tsunemi y, takeuchi m, et al; members of the consensus conference on treatment of skin and mucosal lesions (committee of guideline for the diagnosis and treatment of mucocutaneous lesions of behçet’s disease). guidelines for the treatment of skin and mucosal lesions in behçet’s disease: A secondary publication. J Dermatol. 2020;47:223–235.
   Web of Science ®Google Scholar
• Mat C, Goksugur N, Ergin B, Yurdakul S, Yazici H. The frequency of scarring after genital ulcers in Behcet’s syndrome: a prospective study. Int J Dermatol. 2006;45:554–556.
   Web of Science ®Google Scholar
• Esatoglu SN, Hatemi G. Update on the treatment of Behçet’s syndrome. Intern Emerg Med. 2019;14(5):661–675.
   Web of Science ®Google Scholar
• Alpsoy E, Donmez L, Bacanli A, Apaydin C, Butun B. Review of the clinical manifestations’ chronology in 60 patients with Behçet’s disease. Dermatology. 2003;117:354–356.
   Web of Science ®Google Scholar
• Inaba G. Clinical features of neuro-Behçet’s syndrome. In: Lehner T, Barnes CG, editors. Recent Advances in Behçet’s Disease. London: Royal Society of Medicine Services; 1986:235–246.
   Google Scholar
• Verity DH, Wallace GR, Seed PT, et al. Soluble adhesion molecules in Behcet’s disease. Ocul Immunol InXamm. 1998;6:81–92.
   PubMed Web of Science ®Google Scholar
• Yurdakul S, Hamuryudan V, Yazici H. Behcet syndrome. Curr Opin Rheumatol. 2004;16:38–42.
   PubMedGoogle Scholar
• Saadoun D, Wechsler B, Desseaux K, et al. Mortality in Behçet’s disease. Arthritis Rheum. 2010;62:2806–2812.
   PubMed Web of Science ®Google Scholar
• Siva A, Altintas A, Saip S. Behçet’s syndrome and the nervous system. Curr Opin Neurol. 2004;17:347–357.
   PubMed Web of Science ®Google Scholar
• Sakane T, Takeno M, Suziki N, Inaba G. Behcet’s disease. N Engl J Med. 1999;341:1284–1291.
   PubMed Web of Science ®Google Scholar
• Heper G, Polat M, Yetkin E, Senen K. Cardiac findings in Behçet’s patients. Int J Dermatol. 2010;49(5):574–578.
   Web of Science ®Google Scholar
• Gurgun C, Ercan E, Ceyhan C, et al. Cardiovascular involvement in Behcet’s disease. Jpn Heart J. 2002;43:389–398.
   PubMedGoogle Scholar
• Aslam F, Bandeali SJ, Crowson C, Alam M. Cardiac function and diastolic dysfunction in Behcet's disease: A systematic review and meta-analysis. Int J Rheumatol. 2016;2016:9837184.
   Google Scholar
• Geri G, Wechsler B. Thi Huong du L, Isnard R, Piette JC, Amoura Z, et al. Spectrum of cardiac lesions in behçet disease: a series of 52 patients and review of the literature. Medicine. 2012;91:25–34.
   PubMed Web of Science ®Google Scholar
• van der Heijde D, Aletaha D, Carmona L, et al. Update of the EULAR standardised operating procedures for EULAR-endorsed recommendations. Ann Rheum Dis. 2014;2015(74):8–13.
   Google Scholar
• Fani MM, Ebrahimi H, Pourshahidi S, Aflaki E, Shafiee Sarvestani S. Comparing the effect of phenytoin syrup and triamcinolone acetonide ointment on aphthous ulcers in patients with Behcet’s syndrome. Iran Red Crescent Med J. 2012;14:75–78.
   Web of Science ®Google Scholar
• Alpsoy E, Er H, Durusoy C, Yilmaz E. The use of sucralfate suspension in the treatment of oral and genital ulcerations of Behcet’s disease: a randomised, placebo-controlled and double-blind study. Arch Dermatol. 1999;135:529–532.
   PubMed Web of Science ®Google Scholar
• Hatemi G, Yurttas B, Kutlubay Z, et al. Pentoxifylline Gel for Oral Ulcers in Patients with Behçet’s Syndrome [abstract]. Arthritis Rheumatol. 2019;71(supl):10.
   Google Scholar
• Meiller TF, Kutcher MJ, Overholser CD, Niehaus C, DePaola LG, Siegel MA. Effect of an antimicrobial mouthrinse on recurrent aphthous ulcerations. Oral Surg Oral Med Oral Pathol. 1991;72:425–429.
   Google Scholar
• Addy M, Carpenter R, Roberts WR. Management of recurrent aphthous ulceration. A trial of chlorhexidine gel. Br Dent J. 1976;141:118–120.
   PubMed Web of Science ®Google Scholar
• Kerr AR, Drexel CA, Spielman AI. The efficacy and safety of 50 mg penicillin G potassium troches for recurrent aphthous ulcers. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2003;96:685–694.
   Web of Science ®Google Scholar
• Gorsky M, Epstein J, Raviv A, Yaniv R, Truelove E. Topical minocycline for managing symptoms of recurrent aphthous stomatitis. Spec Care Dentist. 2008;28:27–31.
   PubMedGoogle Scholar
• Graykowski EA, Kingman A. Double-blind trial of tetracycline in recurrent aphthous ulceration. J Oral Pathol. 1978;7:376–382.
   PubMedGoogle Scholar
• Skaare AB, Herlofson BB, Barkvoll P. Mouthrinses containing triclosan reduce the incidence of recurrent aphthous ulcers (RAU). J Clin Periodontol. 1996;23:778–781.
   PubMed Web of Science ®Google Scholar
• Liu J, Zeng X, Chen Q, et al. An evaluation on the efficacy and safety of amlexanox oral adhesive tablets in the treatment of recurrent minor aphthous ulceration in a Chinese cohort: a randomized, double-blind, vehicle-controlled, unparallel multicenter clinical trial. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2006;102:475–481.
   PubMed Web of Science ®Google Scholar
• Collier PM, Neill SM, Copeman PW. Topical 5-aminosalicylic acid: a treatment for aphthous ulcers. Br J Dermatol. 1992;126:185–188.
   PubMed Web of Science ®Google Scholar
• Pourahmad M, Rahiminejad M, Fadaei S, Kashafi H. Effects of camel thorn distillate on recurrent oral aphthous lesions. J Dtsch Dermatol Ges. 2010;8:348–352.
   PubMed Web of Science ®Google Scholar
• Saxen MA, Ambrosius WT. al Rehemtula KF, Russell AL, Eckert GJ. Sustained relief of oral aphthous ulcer pain from topical diclofenac in hyaluronan: a randomized, double-blind clinical trial. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1997;84:356–361.
   PubMed Web of Science ®Google Scholar
• Zand N, Ataie-Fashtami L, Djavid GE, et al. Relieving pain in minor aphthous stomatitis by a single session of non-thermal carbon dioxide laser irradiation. Lasers Med Sci. 2009;24:515–520.
   Web of Science ®Google Scholar
• Alidaee MR, Taheri A, Mansoori P, Ghodsi SZ. Silver nitrate cautery in aphthous stomatitis: a randomized controlled trial. Br J Dermatol. 2005;153:521–525.
   PubMed Web of Science ®Google Scholar
• Chams-Davatchi C, Barikbin B, Shahram F, et al. Pimecrolimus versus placebo in genital aphthous ulcers of Behcet’s disease: a randomized double-blind controlled trial. Int J Rheum Dis. 2010;13:253–258.
   PubMed Web of Science ®Google Scholar
• Kose O, Dinç A, Simsek I. Randomized trial of pimecrolimus cream plus colchicine tablets versus colchicine tablets in the treatment of genital ulcers in Behcet’s disease. Dermatology. 2009;218:140–145.
   PubMed Web of Science ®Google Scholar
• Alpsoy E. New evidence-based treatment approach in Behcet’s disease. Patholog Res Int. 2012;2012:871019.
   Google Scholar
• Angelidis C, Kotsialou Z, Kossyvakis C, et al. Colchicine Pharmacokinetics and Mechanism of Action. Curr Pharm Des. 2018;24:659–663.
   PubMed Web of Science ®Google Scholar
• Aktulga E, Altaç M, Müftüoglu A, et al. A double blind study of colchicine in Behçet’s disease. Haematologica. 1980;65:399–402.
   PubMed Web of Science ®Google Scholar
• Yurdakul S, Mat C, Tuzun Y, et al. A double-blind trial of colchicine in Behçet’s syndrome. Arthritis Rheum. 2001;44:2686–2692.
   PubMed Web of Science ®Google Scholar
• Davatchi F, Sadeghi Abdollahi B, Tehrani Banihashemi A, et al. Colchicine versus placebo in Behcet’s disease: randomized, double-blind, controlled crossover trial. Mod Rheumatol. 2009;19:542–549.
   PubMed Web of Science ®Google Scholar
• Calguneri M, Ertenli I, Kiraz S, Erman M, Celik I. Effect of prophylactic benzathine penicillin on mucocutaneous symptoms of Behcet’s disease. Dermatology. 1996;192:125–128.
   PubMed Web of Science ®Google Scholar
• Mat C, Yurdakul S, Ozyazgan Y, Uysal S, Uysal O, Yazıcı H. A double-blind trial of depot corticosteroids in Behçets syndrome. Rheumatology. 2006;45:348–352.
   PubMed Web of Science ®Google Scholar
• Hatemi G, Melikoglu M, Tunc R, et al. Apremilast for Behcet’s syndrome – a phase 2, placebo-controlled study. N Engl J Med. 2015;16:1510–1518.
   Web of Science ®Google Scholar
• Hatemi G, Mahr A, Ishigatsubo Y, et al. Trial of Apremilast for Oral Ulcers in Behçet’s Syndrome. N Engl J Med. 2019;381:1918–1928.
   PubMed Web of Science ®Google Scholar
• Lopalco G, Venerito V, Leccese P, et al. Real-world effectiveness of apremilast in multirefractory mucosal involvement of Behçet’s disease. Ann Rheum Dis. 2019;78:1736–1737.
   PubMed Web of Science ®Google Scholar
• De Luca G, Cariddi A, Campochiaro C, et al. Efficacy and safety of apremilast for Behçet’s syndrome: a real-life single-centre Italian experience. Rheumatology. 2020;59:171–175.
   PubMed Web of Science ®Google Scholar
• Yazici H, Pazarli H, Barnes CG, et al. A Controlled Trial of Azathioprine in Behçet’s Syndrome. N Engl J Med. 1990;322(5):281–285. doi:10.1056/NEJM199002013220501
   PubMed Web of Science ®Google Scholar
• Melikoglu M, Fresko I, Mat C, et al. Short-term trial of etanercept in Behçet’s disease: a double blind, placebo controlled study.. J Rheumatol. 2005;32(1):98–105.
   PubMed Web of Science ®Google Scholar
• Vallet H, Riviere S, Sanna A, et al. Efficacy of anti-TNF alpha in severe and/or refractory Behçet’s disease: multicenter study of 124 patients. J Autoimmun. 2015;62:67–74. doi:10.1016/j.jaut.2015.06.005
   PubMed Web of Science ®Google Scholar
• Alpsoy E, Durusoy C, Yilmaz E, et al. Interferon alfa-2a in the treatment of Behçet disease: a randomized placebo-controlled and double-blind study. Arch Dermatol. 2002;138(4):467–471. doi:10.1001/archderm.138.4.467
   PubMed Web of Science ®Google Scholar
• Assaad-Khalil SH. Low-dose cyclosporin in Behçet’s disease: follow-up controlled study with emphasis on extraocular manifestations and neuro-Behçet’s disease. In: Jd O, Kokmen E, editors. Behçet’s Disease: Basic and Clinical Aspects. Vols. 603-612. New York: Marcel Dekker; 1991.
   Google Scholar
• Hamuryudan V, et al. Thalidomide in the treatment of the mucocutaneous lesions of the Behcet syndrome. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1998;128(6):443–450. doi:10.7326/0003-4819-128-6-199803150-00004
   PubMed Web of Science ®Google Scholar
• Sharquie KE, Najim RA, Abu-Raghif AR. Dapsone in Behçet’s Disease: A Double-Blind, Placebo-Controlled, Cross-Over Study. J Dermatol. 2002;29(5):267–279. doi:10.1111/j.1346-8138.2002.tb00263.x
   PubMed Web of Science ®Google Scholar
• Sharquie KE, Najim RA, Al-Dori WS, Al-Hayani RK. Oral zinc sulfate in the treatment of Behcet’s disease: A double blind cross-over study. J Dermatol. 2006;33(8):541–546. doi:10.1111/j.1346-8138.2006.00128.x
   Web of Science ®Google Scholar
• Matsuda T, Ohno S, Hirohata S, et al. Efficacy of Rebamipide as Adjunctive Therapy in the Treatment of Recurrent Oral Aphthous Ulcers in Patients with Beh??et??s Disease. Drugs R D. 2003;4(1):19–28. doi:10.2165/00126839-200304010-00002
   Google Scholar
• Sharquie KE, Helmi RM, Noiami AA, Al-Hayani RK, Kadhom MA. The therapeutic role of isotretinoin in the management of Behcet’s disease: a single-blinded, controlled therapeutic study. J Drugs Dermatol. 2013;12:68–73.
   Google Scholar
• Lehner T, Wilton JMA. The therapeutic and immunological effects of levamisole in recurrent oral ulcers and Behçet’s syndrome. In: Lehner T, Cb B, editors. Behçet’s Syndrome: Clinical and Immunological Features. New York: Academic Press; 1979:291–305.
   Google Scholar
• Kose O, Simsek İ, Pay S. Mycophenolate sodium in the treatment of mucocutaneous Behcet’s diseases. Int J Dermatol. 2011;50(7):895–896. doi:10.1111/j.1365-4632.2010.04505.x
   PubMed Web of Science ®Google Scholar
• Cantarini L, Vitale A, Scalini P, et al. Anakinra treatment in drug-resistant Behcet’s disease: a case series. Clin Rheumatol. 2015;34(7):1293–1301. doi:10.1007/s10067-013-2443-8
   PubMed Web of Science ®Google Scholar
• Emmi G, Silvestri E, Cameli AM, et al. Anakinra for resistant Behçet uveitis: why not? Clin Exp Rheumatol. 2013;31(3 Suppl 77):152–153.
   PubMed Web of Science ®Google Scholar
• Caso F, Rigante D, Vitale A, Lucherini OM, Cantarini L. Efficacy of anakinra in refractory Behçet’s disease sacroiliitis. Clin Exp Rheumatol. 2014;32:S171.
   PubMed Web of Science ®Google Scholar
• Ugurlu S, Ucar D, Seyahi E, Hatemi G, Yurdakul S. Canakinumab in a patient with juvenile Behçet’s syndrome with refractory eye disease: figure 1. Ann Rheum Dis. 2012;71(9):1589–1591. doi:10.1136/annrheumdis-2012-201383
   PubMed Web of Science ®Google Scholar
• Vitale A, Rigante D, Caso F, et al. Inhibition of Interleukin-1 by Canakinumab as a Successful Mono-Drug Strategy for the Treatment of Refractory Behçet’s Disease: A Case Series. Dermatology. 2014;228(3):211–214. doi:10.1159/000358125
   PubMed Web of Science ®Google Scholar
• Cantarini L, Vitale A, Borri M, Galeazzi M, Franceschini R. Successful use of canakinumab in a patient with resistant Behçet’s disease. Clin Exp Rheumatol. 2012;30:S115.
   PubMed Web of Science ®Google Scholar
• Emmi G, Talarico R, Lopalco G, et al. Efficacy and safety profile of anti-interleukin-1 treatment in Behçet’s disease: a multicenter retrospective study. Clin Rheumatol. 2016;35(5):1281–1286. doi:10.1007/s10067-015-3004-0
   PubMed Web of Science ®Google Scholar
• Mirouse A, Barete S, Monfort J-B, et al. Ustekinumab for Behçet’s disease. J Autoimmun. 2017;82:41–46. doi:10.1016/j.jaut.2017.05.002
   PubMed Web of Science ®Google Scholar
• Mirouse A, Barete S, Desbois A-C, et al. Long-Term Outcome of Ustekinumab Therapy for Behçet’s Disease. Arthritis Rheumatol. 2019;71(10):1727–1732. doi:10.1002/art.40912
   PubMed Web of Science ®Google Scholar
• Di Scala G, Bettiol A, Cojan RD, Finocchi M, Silvestri E, Emmi G. Efficacy of the anti-IL 17 secukinumab in refractory Behçet’s syndrome: A preliminary study. J Autoimmun. 2019;97:108–113. doi:10.1016/j.jaut.2018.09.002
   PubMed Web of Science ®Google Scholar
• Dincses E, Yurttas B, Esatoglu SN, Melikoglu M, Hamuryudan V, Seyahi E. Secukinumab induced Behçet’s syndrome: a report of two cases. Oxford Medical Case Reports. 2019;2019(5):omz041. doi:10.1093/omcr/omz041
   PubMed Web of Science ®Google Scholar
• Hatemi G, Christensen R, Bang D, et al. update of the EULAR recommendations for the management of Behçet’s syndrome. Ann Rheum Dis. 2018;2018(77):808–818.
   Google Scholar
• Kötter I, Vonthein R, Zierhut M, et al. Differential efficacy of human recombinant interferon-α2a on ocular and extraocular manifestations of behçet disease: results of an open 4-center trial. Semin Arthritis Rheum. 2004;33(5):311–319. doi:10.1016/j.semarthrit.2003.09.005
   PubMed Web of Science ®Google Scholar
• Hamuryudan V, Moral F, Yurdakul S, et al. Systemic interferon alpha 2b treatment in Behçet’s syndrome.. J Rheumatol. 1994;21(6):1098–1100.
   Web of Science ®Google Scholar
• Calguneri M. Effects of interferon alpha treatment on the clinical course of refractory Behcet’s disease: an open study. Ann Rheum Dis. 2003;62(5):492–493. doi:10.1136/ard.62.5.492
   PubMed Web of Science ®Google Scholar
• Moral F, Hamuryudan V, Yurdakul S, Yazici H. Inefficacy of azapropazone in the acute arthritis of Behçet’s syndrome: a randomized, double blind, placebo controlled study.. Clin Exp Rheumatol. 1995;13(4):493–495.
   PubMed Web of Science ®Google Scholar
• Fagni F, Bettiol A, Talarico R, et al. Long-term effectiveness and safety of secukinumab for treatment of refractory mucosal and articular Behçet’s phenotype: a multicentre study. Ann Rheum Dis. 2020;79(8):1098–1104. doi:10.1136/annrheumdis-2020-217108
   PubMed Web of Science ®Google Scholar
• Tugal-Tutkun I, Onal S, Altan-Yaycioglu R, Huseyin Altunbas H, Urgancioglu M. Uveitis in Behçet disease: an analysis of 880 patients. Am J Ophthalmol. 2004;138(3):373–380. doi:10.1016/j.ajo.2004.03.022
   PubMed Web of Science ®Google Scholar
• Ohno S, Namba K, Takemoto Y. Behcet’ s disease. In: Zierhut M, Pavesio C, Ohno S, Orefice F, Na R, editors. Intraocular Inflammation.,Berlin, Heidelberg, New York, Dordrecht, London: Springer-Verlag; 2016:785–795.
   Google Scholar
• Mizuki N, Takeuchi M. Treatment Algorithm of Ocular Behcet’s Disease. Clinical Practice Guidelines for Behcet’s Disease 2020. Tokyo: Shindanto Chiryosha; 2020:56–57.
   Google Scholar
• Masuda K, Urayama A, Kogure M, Nakajima A, Nakae K, Inaba G. DOUBLE-MASKED TRIAL OF CYCLOSPORIN VERSUS COLCHICINE AND LONG-TERM OPEN STUDY OF CYCLOSPORIN IN BEHÇET’S DISEASE. Lancet. 1989;333(8647):1093–1096. doi:10.1016/S0140-6736(89)92381-7
   Google Scholar
• BenEzra D, Cohen E, Chajek T, et al. Evaluation of conventional therapy versus cyclosporine A in Behçet’s syndrome.. Transplant Proc. 1988;20(3 Suppl 4):136–143.
   PubMed Web of Science ®Google Scholar
• Jaffe GJ, Dick AD, Brézin AP, et al. Adalimumab in patients with active noninfectious uveitis. New England Journal of Medicine. 2016;375(10):932–943. doi:10.1056/NEJMoa1509852
   PubMed Web of Science ®Google Scholar
• Silvestri E, Bitossi A, Bettiol A, et al. Adalimumab effectively controls both anterior and posterior noninfectious uveitis associated with systemic inflammatory diseases: focus on Behçet’s syndrome. Inflammopharmacology. 2020;28(3):711–718. doi:10.1007/s10787-020-00697-4
   PubMed Web of Science ®Google Scholar
• Martín-Varillas JL, Atienza-Mateo B, Calvo-Rio V, et al. Biological Therapy in refractory Uveitis due to Behçet’s Disease Collaborative Group. Long Term Follow-up and Optimization of Infliximab in Refractory Uveitis Due to Behçet’s Disease. National Study of 103 Caucasian Patients. J Rheumatol. 2020;1:200300. doi:10.3899/jrheum.200300
   Web of Science ®Google Scholar
• Atienza‐Mateo B, Martín‐Varillas JL, Calvo‐Río V, et al. Comparative Study of Infliximab Versus Adalimumab in Refractory Uveitis due to Behçet’s Disease: national Multicenter Study of 177 Cases. Arthritis Rheumatol. 2019;71(12):2081–2089. doi:10.1002/art.41026
   PubMed Web of Science ®Google Scholar
• Sobaci G, Erdem Ü, Durukan AH, et al. Safety and Effectiveness of Interferon Alpha-2a in Treatment of Patients with Behçet’s Uveitis Refractory to Conventional Treatments. Ophthalmology. 2010;117(7):1430–1435. doi:10.1016/j.ophtha.2009.11.022
   PubMed Web of Science ®Google Scholar
• Lightman S, Taylor SR, Bunce C, et al. Pegylated interferon-α-2b reduces corticosteroid requirement in patients with Behçet’s disease with upregulation of circulating regulatory T cells and reduction of Th17. Ann Rheum Dis. 2015;74(6):1138–1144. doi:10.1136/annrheumdis-2014-205571
   PubMed Web of Science ®Google Scholar
• Tugal-Tutkun I, Pavesio C, De Cordoue A, Bernard-Poenaru O, Gül A. Use of gevokizumab in patients with Behçet’s disease uveitis: an international, randomized, double-masked, placebo-controlled study and open-label extension study. Ocul Immunol Inflamm. 2018;25:1–11.
   Google Scholar
• Dick AD, Tugal-Tutkun I, Foster S, et al. Secukinumab in the treatment of noninfectious uveitis: results of three randomized, controlled clinical trials. Ophthalmology. 2013;120(4):777–787. doi:10.1016/j.ophtha.2012.09.040
   PubMed Web of Science ®Google Scholar
• Deroux A, Chiquet C, Bouillet L. Tocilizumab in severe and refractory Behcet’s disease: four cases and literature review. Semin Arthritis Rheum. 2016;45(6):733–737. doi:10.1016/j.semarthrit.2015.11.012
   PubMed Web of Science ®Google Scholar
• Atienza-Mateo B, Calvo-Río V, Beltrán E, et al. Anti-interleukin 6 receptor tocilizumab in refractory uveitis associated with Behçet’s disease: multicentre retrospective study. Rheumatology. 2018;57(5):856–864. doi:10.1093/rheumatology/kex480
   PubMed Web of Science ®Google Scholar
• Emmi G, Becatti M, Bettiol A, Hatemi G, Prisco D, Fiorillo C. Behçet’s Syndrome as a Model of Thrombo-Inflammation: the Role of Neutrophils. Front Immunol. 2019;1.
   Google Scholar
• Emmi G, Mannucci A, Argento FR, et al. Stem-Cell-Derived Circulating Progenitors Dysfunction in Behçet’s Syndrome Patients Correlates With Oxidative Stress. Front Immunol. 2019;10:2877. doi:10.3389/fimmu.2019.02877
   Web of Science ®Google Scholar
• Ahn JK, Lee YS, Jeon CH, Koh E-M, Cha H-S. Treatment of venous thrombosis associated with Behcet’s disease: immunosuppressive therapy alone versus immunosuppressive therapy plus anticoagulation. Clin Rheumatol. 2008;27(2):201–205. doi:10.1007/s10067-007-0685-z
   PubMed Web of Science ®Google Scholar
• Desbois AC, Wechsler B, Resche-Rigon M, et al. Immunosuppressants reduce venous thrombosis relapse in Behçet’s disease. Arthritis Rheum. 2012;64(8):2753–2760. doi:10.1002/art.34450
   PubMed Web of Science ®Google Scholar
• Alibaz-Oner F, Karadeniz A, Ylmaz S, et al. Behçet disease with vascular involvement: effects of different therapeutic regimens on the incidence of new relapses. Medicine. 2015;94(6):e494. doi:10.1097/MD.0000000000000494
   PubMed Web of Science ®Google Scholar
• Seyahi E, Cakmak OS, Tutar B, et al. Clinical and ultrasonographic evaluation of lower-extremity vein thrombosis in Behcet syndrome: an observational study. Medicine. 2015;94(44):e1899. doi:10.1097/MD.0000000000001899
   PubMed Web of Science ®Google Scholar
• Tascilar K, Melikoglu M, Ugurlu S, et al. Vascular involvement in Behçet’s syndrome: a retrospective analysis of associations and the time course. Rheumatology. 2014;53(11):2018–2022. doi:10.1093/rheumatology/keu233
   PubMed Web of Science ®Google Scholar
• Hamuryudan V, Er T, Seyahi E, et al. Pulmonary artery aneurysms in Behçet syndrome. Am J Med. 2004;117(11):867–870. doi:10.1016/j.amjmed.2004.05.027
   PubMed Web of Science ®Google Scholar
• Saba S, Saricaoğlu S, Bayram B, et al. Arterielle Läsionen beim Morbus Behçet. Vasa. 2003;32(2):75–81. doi:10.1024/0301-1526.32.2.75
   PubMed Web of Science ®Google Scholar
• Hamuryudan V, Seyahi E, Ugurlu S, et al. Pulmonary artery involvement in Behçet׳s syndrome: effects of anti-Tnf treatment. Semin Arthritis Rheum. 2015;45(3):369–373. doi:10.1016/j.semarthrit.2015.06.008
   PubMed Web of Science ®Google Scholar
• Hamuryudan V, Yurdakul S, Moral F, et al. PULMONARY ARTERIAL ANEURYSMS IN BEHÇET’S SYNDROME: A REPORT OF 24 CASES. Br J Rheumatol. 1994;33(1):48–51. doi:10.1093/rheumatology/33.1.48
   PubMedGoogle Scholar
• Seyahi E, Melikoglu M, Akman C, et al. Pulmonary Artery Involvement and Associated Lung Disease in Behçet Disease. Medicine. 2012;91(1):35–48. doi:10.1097/MD.0b013e318242ff37
   PubMed Web of Science ®Google Scholar
• Le Thi HD, Wechsler B, Papo T, et al. Arterial lesions in Behçet’s disease. A study in 25 patients.. J Rheumatol. 1995;22(11):2103–2113.
   Web of Science ®Google Scholar
• Saadoun D, Asli B, Wechsler B, et al. Long-term outcome of arterial lesions in Behçet disease: a series of 101 patients. Medicine. 2012;91(1):18–24. doi:10.1097/MD.0b013e3182428126
   PubMed Web of Science ®Google Scholar
• Park M-C, Hong B-K, Kwon HM, Hong Y-S. Surgical outcomes and risk factors for postoperative complications in patients with Behcet’s disease. Clin Rheumatol. 2007;26(9):1475–1480. doi:10.1007/s10067-006-0530-9
   Web of Science ®Google Scholar
• Ding Y, Li C, Liu J, et al. Tocilizumab in the treatment of severe and/or refractory vasculo-Behçet’s disease: a single-centre experience in China.. Rheumatology. 2018;57(11):2057–2059. doi:10.1093/rheumatology/key230
   PubMed Web of Science ®Google Scholar
• Pipitone N, Olivieri I, Padula A, et al. Infliximab for the treatment of Neuro-Behçet’s disease: A case series and review of the literature. Arthritis Rheum. 2008;59(2):285–290. doi:10.1002/art.23345
   PubMed Web of Science ®Google Scholar
• Borhani Haghighi A, Safari A, Nazarinia MA, Habibagahi Z, Shenavandeh S. Infliximab for patients with neuro-Behcet’s disease: case series and literature review. Clin Rheumatol. 2011;30(7):1007–1012. doi:10.1007/s10067-011-1726-1
   Web of Science ®Google Scholar
• Zeydan B, Uygunoglu U, Saip S, et al. Infliximab is a plausible alternative for neurologic complications of Behçet disease. Neurol Neuroimmunol Neuroinflamm. 2016;3(5):e258. doi:10.1212/NXI.0000000000000258
   PubMed Web of Science ®Google Scholar
• Asa A-A, Saip S. Treatment of NeuroBehcet’s disease with infliximab: an international multi-centre case-series of 18 patients. Clin Exp Rheumatol. 2010;28(Suppl 60):S119.
   Google Scholar
• Noel N, Bernard R, Wechsler B, Resche-Rigon M, Depaz R. Long-Term Outcome of Neuro-Behçet’s Disease. Arth Rheumatol. 2014;66(5):1306–1314. doi:10.1002/art.38351
   PubMed Web of Science ®Google Scholar
• Addimanda O, Pipitone N, Pazzola G, Salvarani C. Tocilizumab for severe refractory neuro-Behçet: three cases IL-6 blockade in neuro-Behçet. Semin Arthritis Rheum. 2015;44(4):472–475. doi:10.1016/j.semarthrit.2014.08.004
   PubMed Web of Science ®Google Scholar
• Monastirli A, Chroni E, Georgiou S, et al. Interferon- treatment for acute myelitis and intestinal involvement in severe Behcet’s disease. QJM. 2010;103(10):90. doi:10.1093/qjmed/hcq125
   Web of Science ®Google Scholar
• Nichols JC, Ince A, Akduman L, Mann ES. Interferon-alpha 2a treatment of neuro-Behcet disease. J Neuroophthalmol. 2001;21(2):109–111. doi:10.1097/00041327-200106000-00011
   Web of Science ®Google Scholar
• Hirohata S, Kikuchi H, Sawada T, et al. Retrospective analysis of long-term outcome of chronic progressive neurological manifestations in Behcet’s disease. J Neurol Sci. 2015;349(1–2):143–148. doi:10.1016/j.jns.2015.01.005
   PubMed Web of Science ®Google Scholar
• Shugaiv E, Tuzun E, Mutlu M, Kiyat-Atamer A, Kurtuncu M, Akman-Demir G. Mycophenolate mofetil as a novel immunosuppressant in the treatment of neuro-Behçet’s disease with parenchymal involvement: presentation of four cases.. Clin Exp Rheumatol. 2011;29(4 Suppl 67):S64–S67.
   PubMed Web of Science ®Google Scholar
• Kato Y, Numaga J, Kato S, Kaburaki T, Kawashima H, Fujino Y. Central nervous system symptoms in a population of Behçet’s disease patients with refractory uveitis treated with cyclosporine A. Clin Exp Ophthalmol. 2001;29:335–336.
   PubMed Web of Science ®Google Scholar
• Kotake S, Higashi K, Yoshikawa K, Sasamoto Y, Okamoto T, Matsuda H. Central nervous system symptoms in patients with Behçet disease receiving cyclosporine therapy. Ophthalmology. 1999;106(3):586–589. doi:10.1016/S0161-6420(99)90120-3
   PubMed Web of Science ®Google Scholar
• Kötter I, Günaydin I, Batra M, et al. CNS involvement occurs more frequently in patients with Behçet’s disease under cyclosporin A (CSA) than under other medications—results of a retrospective analysis of 117 cases. Clin Rheumatol. 2006;25(4):482–486. doi:10.1007/s10067-005-0070-8
   PubMed Web of Science ®Google Scholar
• Akman-Demir G, Ayranci O, Kurtuncu M, Vanli EN, Mutlu M, Tugal-Tutkun I. Cyclosporine for Behçet’s uveitis: is it associated with an increased risk of neurological involvement? Clin Exp Rheumatol. 2008;26(4 Suppl 50):S84–90.
   PubMed Web of Science ®Google Scholar
• Saadoun D, Wechsler B, Resche-Rigon M, et al. Cerebral venous thrombosis in Behçet’s disease. Arthritis Rheum. 2009;61(4):518–526. doi:10.1002/art.24393
   PubMed Web of Science ®Google Scholar
• Ferro JM, Canhao P, Stam J, Bousser M-G. Prognosis of cerebral vein and dural sinus thrombosis: results of the International Study on Cerebral Vein and Dural Sinus Thrombosis (ISCVT). Stroke. 2004;35(3):664–670. doi:10.1161/01.STR.0000117571.76197.26
   PubMed Web of Science ®Google Scholar
• Watanabe K, Tanida S, Inoue N, et al. Evidence-based diagnosis and clinical practice guidelines for intestinal Behçet’s disease 2020 edited by Intractable Diseases, the Health and Labour Sciences Research Grants. J Gastroenterol. 2020;55(7):679–700. doi:10.1007/s00535-020-01690-y
   PubMed Web of Science ®Google Scholar
• Hisamatsu T, Ueno F, Matsumoto T, et al. The 2nd edition of consensus statements for the diagnosis and management of intestinal Behçet’s disease: indication of anti-TNFα monoclonal antibodies. J Gastroenterol. 2014;49(1):156–162. doi:10.1007/s00535-013-0872-4
   PubMed Web of Science ®Google Scholar
• Hisamatsu T, Hayashida M. Treatment and outcomes: medical and surgical treatment for intestinal Behçet’s disease. Intest Res. 2017;15(3):318–327. doi:10.5217/ir.2017.15.3.318
   Web of Science ®Google Scholar
• Park YE, Cheon JH. Updated treatment strategies for intestinal Behçet’s disease. Korean J Intern Med. 2018;33:1–19.
   PubMed Web of Science ®Google Scholar
• Iwata S, Saito K, Yamaoka K, et al. Efficacy of combination therapy of anti-TNF-α antibody infliximab and methotrexate in refractory entero-Behçet’s disease. Mod Rheumatol. 2011;21:184–191.
   PubMed Web of Science ®Google Scholar
• Ideguchi H, Suda A, Takeno M, et al. Gastrointestinal manifestations of Behcet’s disease in Japan: a study of 43 patients. Rheumatol Int. 2014;34:851–856.
   PubMed Web of Science ®Google Scholar
• Hibi T, Hirohata S, Kikuchi H, et al. Infliximab therapy for intestinal, neurological, and vascular involvement in Behcet disease: efficacy, safety, and pharmacokinetics in a multicenter, prospective, open-label, single-arm phase 3 study. Medicine. 2016;95:3863.
   PubMed Web of Science ®Google Scholar
• Zou J, Ji DN, Shen Y, Guan JL, Zheng SB. Mucosal healing at 14 weeks predicts better outcome in low-dose infliximab treatment for Chinese patients with active intestinal Behcet’s disease. Ann Clin Lab Sci. 2017;47:171–177.
   Web of Science ®Google Scholar
• Tanida S, Inoue N, Kobayashi K, et al. Adalimumab for the treatment of Japanese patients with intestinal Behcet’s disease. Clin Gastroenterol Hepatol. 2015;13:940.
   PubMed Web of Science ®Google Scholar
• Inoue N, Kobayashi K, Naganuma M, et al. Long-term safety and efficacy of adalimumab for intestinal Behcet’s disease in the open label study following a phase 3 clinical trial. Intest Res. 2017;15:395–401.
   PubMed Web of Science ®Google Scholar
• Vitale A, Emmi G, Lopalco G, et al. Adalimumab effectiveness in Behcet’s disease: short and longterm data from a multicenter retrospective observational study. Clin Rheumatol. 2017;36:451–455.
   PubMed Web of Science ®Google Scholar
• Ma D, Zhang CJ, Wang RP, Wang L, Yang H. Etanercept in the treatment of intestinal Behcet’s disease. Cell Biochem Biophys. 2014;69:735–739.
   Web of Science ®Google Scholar
• Vitale A, Emmi G, Lopalco G, et al. Long-term efficacy and safety of golimumab in the treatment of multirefractory Behcet’s disease. Clin Rheumatol. 2017;36:2063–2069.
   PubMed Web of Science ®Google Scholar
• Lopalco G, Emmi G, Gentileschi S, et al. Certolizumab pegol treatment in Behcet’s disease with different organ involvement: a multicenter retrospective observational study. Mod Rheumatol. 2017;27:1031–1035.
   PubMed Web of Science ®Google Scholar
• Sayarlioglu M, Kotan MC, Topcu N, Bayram I, Arslanturk H, Gul A. Treatment of recurrent perforating intestinal ulcers with thalidomide in Behçet’s disease. Ann Pharmacother. 2004;38:808–811.
   Web of Science ®Google Scholar
• Yasui K, Uchida N, Akazawa Y, et al. Thalidomide for treatment of intestinal involvement of juvenile-onset Behçet disease. Inflamm Bowel Dis. 2008;14:396–400.
   PubMed Web of Science ®Google Scholar
• Hatemi I, Hatemi G, Pamuk ON, Erzin Y, Celik AF. TNF-alpha antagonists and thalidomide for the management of gastrointestinal Behçet’s syndrome refractory to the conventional treatment modalities: a case series and review of the literature. Clin Exp Rheumatol. 2015;33(6 Suppl 94):129–137.
   PubMed Web of Science ®Google Scholar
• Park Y, Cheon JH. Update on the Treatment of Behcet’s Disease of the Small Bowel with Biologic Agents. Curr Gastroenterol Rep. 2020;19(22):24.
   Google Scholar
• Demirelli S, Degirmenci H, Inci S, Arisoy A. Cardiac manifestations in Behcet;s disease. Intractable Rare Dis Res. 2015;4:70–75.
   PubMed Web of Science ®Google Scholar
• Ozatli D, Kav T, Haznedaroglu IC, et al. Cardiac and great vessel thrombosis in Behcet's disease. Intern Med. 2001;40:68–72.
   Web of Science ®Google Scholar
• Ozeren M, Dogan OV, Dogan S, Yucel E. True and pseudo aneurysms of coronary arteries in a patient with Behçet’s disease. Eur J Cardiothorac Surg. 2004;25:465–467.
   Web of Science ®Google Scholar
• Kaatz M, Görnig M, Bocker T, Zouboulis CC, Wollina U. Late manifestation of a fatal Behcet's disease with cardiac involvement and lethal outcome. Dtsch Med Wochenschr. 1998;123:217–222.
   Web of Science ®Google Scholar
• Kwon CM, Lee SH, Kim JH, et al. A case of Behcet's disease with pericarditis, thrombotic thrombocytopenic purpura, deep vein thrombosis and coronary artery pseudo aneurysm. Korean J Intern Med. 2006;21:50–56.
   PubMedGoogle Scholar
• Al-Na’mah ZM, Carson R, Thanoon IA. Dexamucobase: a novel treatment for oral aphthous ulceration. Quintessence Int. 2009;40:399–404.
   Web of Science ®Google Scholar
• Ghate J, Jorizzo J. Behcet’s disease and complex aphthosis. J Am Acad Dermatol. 1999;40:1–18.
   PubMed Web of Science ®Google Scholar
• Binnie WH, Curro FA, Khandwala A, Van Inwegan RG. Amlexanox oral paste: a novel treatment that accelerates the healing of aphthous ulcers. Compend Contin Educ Dent. 1997;18:1116–1124.
   PubMedGoogle Scholar
• Greer RO, Lindenmuth JE, Juarez T, Khandwala A. A double blind study of topically applied 5% amlexanox in the treatment of aphthous ulcers. J Oral Maxillofac Surg. 1993;51:243–248.
   PubMed Web of Science ®Google Scholar
• Arabaci T, Kara C, Ciçek Y. Relationship between periodontal parameters and Behçet’s disease and evaluation of different treatments for oral recurrent aphthous stomatitis. J Periodontal Res. 2009;44:718–725.
   PubMed Web of Science ®Google Scholar
• Gorsky M, Epstein J, Rabenstein S, Elishoov H, Yarom N. Topical minocycline and tetracycline rinses in treatment of recurrent aphthous stomatitis: a randomized cross-over study. Dermatol Online J. 2007;13:1.
   PubMedGoogle Scholar
• Wechsler B, Bodaghi B, Thi Huong DL, et al. Efficacy of interferon alfa-2a in severe and refractory uveitis associated with Behçet’s disease. Ocul Immunol Inflamm. 2000;8:293–301.
   PubMed Web of Science ®Google Scholar
• Fabiani C, Vitale A, Emmi G, et al. Interleukin (IL)-1 inhibition with anakinra and canakinumab in Behçet’s disease-related uveitis: a multicenter retrospective observational study. Clin Rheumatol. 2017;36:191–197.
   PubMed Web of Science ®Google Scholar